Zilongjin tablets as an adjunct therapy to conventional chemotherapy in patients with non-squamous non-small cell lung cancer: a randomized and controlled clinical trial

An evaluation method features the global value of an individual’s dynamic information for the clinical assessment of Traditional Chinese Medical adjuvant therapy of tumor

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-15007683

Enrollment

Unknown

Registered

2015-12-31

Start date

2016-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-squamous non-small cell lung cancer

Interventions

1:conventional chemotherapy + Zilongjin tablets

2:conventional chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: non-squamous non-small cell lung cancer, IIIB to IV stage; TCM diagnosis of asthenia of qi and blood; without chemotherapy or radiotherapy, after chemotherapy or radiotherapy for more than 1 month, unsuitable for operation or refuse surgery, Recurrence after surgery, cancer metastasis after after operation; Karnofsky Performance score of 60% or higher; Liver and kidney function were normal; Expected survival time is more than 3 months; aged 18 to 75 years; With observable tumor foci; Provision of written informed consent by participants or surrogates.

Exclusion criteria

Exclusion criteria: History of allergic to platinum compounds; poor compliance; Women during pregnancy or lactation; Has a serious cardiovascular disease, Liver lesions and kidney disease with other serious diseases; undergoing chemotherapy, radiotherapy, targeted therapy, biological treatment and so on; after chemotherapy or radiotherapy for less than 1 month

Design outcomes

Primary

Measure	Time frame
total effective rate;Quality-adjusted survival time;	—

Secondary

Measure	Time frame
Over Survival;FACT-G 4.0;	—

Countries

China

Contacts

Public ContactZhai Jingbo

zhaijingbo@foxmail.com+86 13820176106

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026